Cited 40 times in
P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2020-07-03T17:05:56Z | - |
dc.date.available | 2020-07-03T17:05:56Z | - |
dc.date.issued | 1997 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/177270 | - |
dc.description.abstract | Expression and clinical relevance of p-glycoprotein (p-gp) were evaluated in 31 cases of locally advanced breast cancer and 9 cases involving inflammatory breast cancer after induction chemotherapy. The de novo p-gp expression rate was 26% and increased up to 58% (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Although more clinically complete responders were found in the secondary p-gp negative group (p = 0.02), this difference was not found in pathological tumor response. Moreover, as the grade of the secondary p-gp expression increased, the chemotherapeutic effect decreased, suggesting an inverse relationship between p-gp expression and drug effect (p = 0.04). When we subgrouped the patients into 4 groups using these two parameters, p-gp negative patients presenting with a high drug effect showed a low recurrence rate (p = 0.05) and marginal survival benefits (p = 0.09) as opposed to patients with a low drug effect. But in p-gp positive groups, the recurrence rate was the same between the two groups regardless of the drug effect. Thus, in the p-gp negative patient with a high drug effect, adjuvant chemotherapy with the same regimen as induction chemotherapy may induce more prognostically favorable results. Therefore, clinical application of the secondary p-gp detection can be used as an intermediate endpoint in evaluating drug response for an induction regimen. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Kluwer Academic | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/metabolism | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/drug therapy* | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/metabolism | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/pathology | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Drug Resistance, Multiple* | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.title | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Jin Sik Min | - |
dc.contributor.googleauthor | Kyung Sik Lee | - |
dc.contributor.googleauthor | Byung Soo Kim | - |
dc.contributor.googleauthor | Kyi Beom Lee | - |
dc.identifier.doi | 10.1023/a:1005739525196 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 9116319 | - |
dc.identifier.url | https://link.springer.com/article/10.1023/a%3A1005739525196 | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | 김주항 | - |
dc.contributor.affiliatedAuthor | 노재경 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 65 | - |
dc.citation.endPage | 72 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, Vol.42(1) : 65-72, 1997 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.